Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Medical Oncology
Published in: Medical Oncology 1/2008

01-03-2008 | Original Paper

Vascular endothelial growth factor gene 936 C/T polymorphism in breast cancer patients

Authors: Aydan Eroğlu, Ayşenur Öztürk, Ragıp Çam, Nejat Akar

Published in: Medical Oncology | Issue 1/2008

Login to get access

Excerpt

Angiogenesis is an important step in the development, growth, and metastasis of malignant tumor. Vascular endothelial growth factor (VEGF) is one of the most potent endothelial cell mitogens and plays an important role in angiogenesis. High level of VEGF and increased microvessel density in tumors are associated with an advanced stage disease and worse prognosis for several types of malignant tumors, including breast cancer [1, 2]. …
Literature
1.
Poon RT, Fan ST, Wong J, et al. Clinical implications of circulating angiogenic factor in cancer patients. J Clin Oncol 2001;19:1207–25.PubMed
2.
Gasparini G, Toi M, Gion M, et al. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 1997;89:139–47.PubMedCrossRef
3.
Vincenti V, Cassano C, Roschi M, Persico G. Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. Circulation 1996;93:1493–95.PubMed
4.
Krippl P, Langsenlehner U, Renner W, Yazdani-Biuki B, Wolf G, Wascher TC, Paulweber B, Haas J, Samonigg H. A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. Int J Cancer 2003;106:468–71.PubMedCrossRef
5.
Kataoka N, Cai Q, Wen W, Shu XO, Jin F, Gao YT, Zheng W. Population-based case-control study of VEGF gene polymorphisms and breast cancer risk among Chinese women. Cancer Epidemiol Biomarkers Prev 2006;15:1148–52.PubMedCrossRef
6.
Jin Q, Hemminki K, Enquist K, Lenner P, et al. Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis. Clin Cancer Res 2005;11:3647–53.PubMedCrossRef
7.
Jacobs EJ, Feigelson HS, Bain EB, Brady KA, Rodriguez C, Stevens VL, Patel AV, Thun MJ, Calle EE. Polymorphisms in the vascular endothelial growth factor gene and breast cancer in the cancer prevention study II cohort. Breast Cancer Res 2006;8:R22.PubMedCrossRef
8.
Howell WM, Bateman AC, Turner SJ, Collins A, Theaker JM. Influence of vascular endothelial growth factor single nucleotide polymorphisms on tumour development in cutaneous malignant melanoma. Genes Immun 2002;3:229–32.PubMedCrossRef
9.
Lee SJ, Lee SY, Jeon HS, et al. Vascular endothelial growth factor gene polymorphisms and risk of primary lung cancer. Cancer Epidemiol Biomarkers Prev 2005;14:571–5.PubMedCrossRef
10.
Sfar S, Hassen E, Saad H, Mosbah F, Chouchane L. Association of VEGF genetic polymorphism with prostate carcinoma risk and clinical outcome. Cytokine 2006;35:21–8.PubMedCrossRef
11.
Renner W, Kotschan S, Hoffman C, Obermayer-Pietsch B, Pilger E. A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Res 2000;37:443–8.PubMedCrossRef
12.
Eroglu A, Gulec S, Kurtman C, Cam R, Akar N. Vascular endothelial growth factor 936 C/T polymorphism in cancer patients. Ann Oncol 2006;17:1467–68.PubMedCrossRef
Metadata
Title
Vascular endothelial growth factor gene 936 C/T polymorphism in breast cancer patients
Authors
Aydan Eroğlu
Ayşenur Öztürk
Ragıp Çam
Nejat Akar
Publication date
01-03-2008
Publisher
Humana Press Inc
Published in
Medical Oncology / Issue 1/2008
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-007-0046-4

Other articles of this Issue 1/2008

Medical Oncology 1/2008 Go to the issue

Original Paper

Cancer during pregnancy: 10-year experience at a regional cancer reference center in Mexico

Original Paper

Inhibitory effect of Hypoxia inducible factor-1 antisense oligonucleotide on growth of human hepatocellular carcinoma cells

Original Paper

Liver embolizations in oncology: A review

Original Paper

Thiopurine S-methyltransferase Gene (TMPT) polymorphisms in a Mexican population of healthy individuals and leukemic patients

Original Paper

Anaemia of cancer: an overview of mechanisms involved in its pathogenesis

Original Paper

Epigallocatechin-3-gallate induces apoptosis and cell cycle arrest in HTLV-1-positive and -negative leukemia cells
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits